Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

PTIX

Protagenic Therapeutics Inc

Apr 19 • 12:38PM ET

1.27

Dollar change -0.10
Percentage change -6.93	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: VXF

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-1.15	Insider Own	19.99%	Shs Outstand	4.44M	Perf Week	-11.46%
Market Cap	5.66M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	3.55M	Perf Month	-5.56%
Income	-5.00M	PEG	-	EPS next Q	-	Inst Own	7.96%	Short Float	0.32%	Perf Quarter	48.26%
Sales	0.00M	P/S	-	EPS this Y	-	Inst Trans	-1.74%	Short Ratio	1.07	Perf Half Y	58.39%
Book/sh	0.83	P/B	1.54	EPS next Y	-	ROA	-80.91%	Short Interest	0.01M	Perf Year	-34.62%
Cash/sh	0.91	P/C	1.39	EPS next 5Y	-	ROE	-94.48%	52W Range	0.68 - 2.32	Perf YTD	28.79%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-2.91%	ROI	-136.32%	52W High	-45.04%	Beta	-
Dividend TTM	-	Quick Ratio	6.41	Sales past 5Y	0.00%	Gross Margin	-	52W Low	87.58%	ATR (14)	0.16
Dividend Ex-Date	-	Current Ratio	6.41	EPS Y/Y TTM	-39.72%	Oper. Margin	0.00%	RSI (14)	40.46	Volatility	13.70% 13.02%
Employees	3	Debt/Eq	0.00	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	16.00
Option/Short	No / Yes	LT Debt/Eq	0.00	EPS Q/Q	-175.07%	Payout	-	Rel Volume	0.65	Prev Close	1.37
Sales Surprise	-	EPS Surprise	37.50%	Sales Q/Q	-	Earnings	Apr 01 AMC	Avg Volume	10.63K	Price	1.27
SMA20	-19.42%	SMA50	1.97%	SMA200	-3.93%	Trades		Volume	3,515	Change	-6.93%

Apr-17-24 08:42AM	Protagenic Therapeutics' Innovative Peptide PT00114 to be Highlighted at Boston Summit (ACCESSWIRE)
Apr-01-24 09:53PM	PTIX Stock Earnings: Protagenic Therapeutics Reported Results for Q4 2023 (InvestorPlace)
04:20PM	Protagenic Therapeutics Reports Fourth Quarter and Full Year 2023 Results (ACCESSWIRE)
Mar-27-24 08:42AM	Protagenic Therapeutics Successfully Concludes Third Cohort in Single Dose Portion of Phase 1 Trial for Stress-Related Neuropsychiatric Disorders (ACCESSWIRE)
Mar-25-24 05:00PM	Protagenic Therapeutics Schedules First Q4 and FY 2023 Earnings Call (ACCESSWIRE) +12.37%
08:41AM	Loading…
Mar-21-24 08:41AM	Protagenic Therapeutics Announces Resolution of Nasdaq Deficiency Notice (ACCESSWIRE) +5.93%
Feb-13-24 08:30AM	Protagenic Therapeutics Achieves First Clinical Safety Milestone with its Novel Neuropeptide for the Potential Treatment of Stress-Related Disorders (ACCESSWIRE)
Dec-12-23 07:30AM	Protagonist Reports 2-Year Follow Up Data from Rusfertide REVIVE Study at the ASH Annual Meeting Showing Durable Efficacy and No New Safety Signals (ACCESSWIRE) +15.65%
Oct-13-23 09:00AM	Protagenic Therapeutics Announces Date of Annual Shareholder Meeting (ACCESSWIRE) +13.49%
Sep-26-23 08:18AM	Protagenic Therapeutics Initiates Phase I/IIa Clinical Trial for Groundbreaking Brain Peptide PT00114 (ACCESSWIRE)
Mar-22-23 12:55PM	Protagenic Therapeutics to Effect 1-for-4 Reverse Stock Split (ACCESSWIRE) +20.97%
Apr-26-22 08:15AM	Protagenic Therapeutics to Present at the B. Riley Securities Neuro and Ophthalmology Virtual Investor Conference on April 27th (ACCESSWIRE) -5.75%
Nov-16-21 09:58AM	Protagenic Therapeutics Announces Third Quarter 2021 Results and Business Update (GlobeNewswire)
Aug-30-21 09:15AM	Protagenic Therapeutics to Host Virtual Science Review Wednesday, September 8th at 10 AM ET (GlobeNewswire)
Aug-17-21 07:45AM	Protagenic Therapeutics Announces Second Quarter 2021 Results and Provides Business Update (GlobeNewswire)
04:21PM	Loading…
Jul-23-21 04:21PM	Protagenic Therapeutics Updates Timeline for Commencement of Patient Enrollment for PT00114 Clinical Trial (GlobeNewswire)
Jul-08-21 11:20AM	50+ Companies to Present at the Access to Giving Virtual Investor Conference on July 13th - 15th, 2021 (ACCESSWIRE) +8.75%
Jul-06-21 06:17AM	Protagenic Therapeutics to Host Webinar with Dr. Maurizio Fava for its Lead Molecule PT00114 on Tuesday, July 13th at 10:00 AM ET (GlobeNewswire)
Jun-23-21 09:35AM	50+ Companies to Present at the Access to Giving Virtual Investor Conference on July 13th - 15th, 2021 (ACCESSWIRE) +10.47%
Jun-16-21 09:15AM	Protagenic Therapeutics to Present at the H.C. Wainwright Psychedelics in Psychiatry and Beyond Virtual Conference on June 17th (GlobeNewswire)
Apr-29-21 03:06PM	Protagenic Therapeutics, Inc. Announces Closing of $13.2 Million Public Offering and Uplisting to Nasdaq (GlobeNewswire) +5.36%
Apr-26-21 08:58PM	Protagenic Therapeutics, Inc. Announces Nasdaq Uplisting and Pricing of $13.2 Million Public Offering (GlobeNewswire) -24.29%
Dec-16-20 09:15AM	Dr. Maurizio Fava of Massachusetts General Hospital to Serve as Principal Investigator for PT00114 Clinical Trial (GlobeNewswire)
Sep-08-20 12:10PM	Protagenic Therapeutics Completes $2.0 Million Convertible Note Financing (GlobeNewswire)

Protagenic Therapeutics, Inc. operates as a biotechnology company. It engages in the discovery and development of therapeutics to treat stress-related disorders including post-traumatic stress disorder, depression, anxiety, and drug & alcohol addiction. The firm offers PT00114 peptide-based formulations. The company was founded by Garo H. Armen, David A. Lovejoy, and Hartoun Hartounian on February 3, 1994 and is headquartered in New York, NY.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Arrow Alexander K.	Chief Financial Officer	Oct 12 '23	Buy	0.81	8,000	6,480	45,815	Oct 13 12:48 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

PTIX

Protagenic Therapeutics Inc

Upgrade your FINVIZ experience